Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)

Lipopeptide vaccines elicited sustainable CD4+ and CD8+ T-cell responses, following IM or ID administration. CD8+ T-cell responses had shifted and expanded to different epitopes after one year of follow-up. These results should facilitate the design of the next generation of prime-boost trials with repeated doses of lipopeptide vaccines.